Eastern Insurance Company Limited (DSE:EASTERNINS)
45.40
-0.60 (-1.30%)
At close: Aug 7, 2025
SpringWorks Therapeutics Income Statement
Financials in millions BDT. Fiscal year is January - December.
Millions BDT. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Premiums & Annuity Revenue | 177.05 | 131.13 | 143.44 | 265.46 | 327 | 294.48 | Upgrade |
Total Interest & Dividend Income | 165.1 | 169.77 | 102.62 | 106.99 | 88.6 | 104.66 | Upgrade |
Gain (Loss) on Sale of Investments | 0.38 | 0.38 | 3 | 12.24 | 74.12 | -25.97 | Upgrade |
Other Revenue | 20.08 | 19.32 | 23.42 | 57.11 | 62.52 | 54.21 | Upgrade |
362.61 | 320.6 | 272.47 | 441.81 | 552.23 | 427.38 | Upgrade | |
Revenue Growth (YoY) | 15.10% | 17.66% | -38.33% | -19.99% | 29.21% | 4.23% | Upgrade |
Policy Benefits | 45.92 | 28.24 | 30.39 | 41.46 | 65.85 | 21.2 | Upgrade |
Policy Acquisition & Underwriting Costs | 65.1 | 39.82 | 39.81 | 38.22 | 38.72 | 69.13 | Upgrade |
Depreciation & Amortization | 16.85 | 16.85 | 16.71 | 14.04 | 14.53 | 14.43 | Upgrade |
Selling, General & Administrative | 123.47 | 123.47 | 148.19 | 159.39 | 188.57 | 110.36 | Upgrade |
Total Operating Expenses | 251.35 | 208.39 | 235.1 | 253.11 | 307.66 | 215.12 | Upgrade |
Operating Income | 111.26 | 112.21 | 37.37 | 188.7 | 244.57 | 212.25 | Upgrade |
Interest Expense | -1.8 | -1.8 | -1.68 | -1.28 | -0.77 | - | Upgrade |
Other Non Operating Income (Expenses) | -1.04 | -1.04 | -1.31 | -2.39 | -1.36 | -1.23 | Upgrade |
EBT Excluding Unusual Items | 108.42 | 109.37 | 34.38 | 185.03 | 242.44 | 211.02 | Upgrade |
Pretax Income | 108.42 | 109.37 | 34.38 | 185.03 | 242.44 | 211.02 | Upgrade |
Income Tax Expense | 35.66 | 36.47 | 24.82 | 50.27 | 46.63 | 43.52 | Upgrade |
Net Income | 72.76 | 72.9 | 9.56 | 134.77 | 195.81 | 167.5 | Upgrade |
Net Income to Common | 72.76 | 72.9 | 9.56 | 134.77 | 195.81 | 167.5 | Upgrade |
Net Income Growth | 174.44% | 662.45% | -92.91% | -31.17% | 16.90% | 3.02% | Upgrade |
Shares Outstanding (Basic) | 43 | 43 | 43 | 43 | 43 | 43 | Upgrade |
Shares Outstanding (Diluted) | 43 | 43 | 43 | 43 | 43 | 43 | Upgrade |
EPS (Basic) | 1.69 | 1.69 | 0.22 | 3.13 | 4.54 | 3.89 | Upgrade |
EPS (Diluted) | 1.69 | 1.69 | 0.22 | 3.13 | 4.54 | 3.89 | Upgrade |
EPS Growth | 174.44% | 662.45% | -92.91% | -31.17% | 16.90% | 3.02% | Upgrade |
Free Cash Flow | 60.87 | 51.63 | -6.23 | 133.37 | 253.88 | 168.29 | Upgrade |
Free Cash Flow Per Share | 1.41 | 1.20 | -0.14 | 3.09 | 5.89 | 3.90 | Upgrade |
Dividend Per Share | 1.500 | 1.500 | 2.000 | 2.200 | 2.200 | 2.000 | Upgrade |
Dividend Growth | -25.00% | -25.00% | -9.09% | - | 10.00% | - | Upgrade |
Operating Margin | 30.68% | 35.00% | 13.72% | 42.71% | 44.29% | 49.66% | Upgrade |
Profit Margin | 20.07% | 22.74% | 3.51% | 30.50% | 35.46% | 39.19% | Upgrade |
Free Cash Flow Margin | 16.79% | 16.10% | -2.29% | 30.19% | 45.98% | 39.38% | Upgrade |
EBITDA | 114.38 | 115.44 | 54.08 | 202.74 | 249.73 | 218.05 | Upgrade |
EBITDA Margin | 31.54% | 36.01% | 19.85% | 45.89% | 45.22% | 51.02% | Upgrade |
D&A For EBITDA | 3.12 | 3.23 | 16.71 | 14.04 | 5.17 | 5.8 | Upgrade |
EBIT | 111.26 | 112.21 | 37.37 | 188.7 | 244.57 | 212.25 | Upgrade |
EBIT Margin | 30.68% | 35.00% | 13.72% | 42.71% | 44.29% | 49.66% | Upgrade |
Effective Tax Rate | 32.89% | 33.35% | 72.19% | 27.17% | 19.23% | 20.63% | Upgrade |
Source: S&P Global Market Intelligence. Insurance template. Financial Sources.